From: I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma
I-124 codrituzumab 10 mg (n = 14) | I-124 codrituzumab 2.5–5 mg/kg (n = 7) | |||
---|---|---|---|---|
Target organ | Mean cGy/37 MBq | SD | Mean cGy/37 MBq | SD |
Adrenals | 1.14 | 0.17 | 1.57 | 0.33 |
Brain | 0.60 | 0.14 | 0.84 | 0.19 |
Breasts | 0.71 | 0.12 | 1.01 | 0.21 |
Gallbladder wall | 1.18 | 0.18 | 1.60 | 0.33 |
LLI wall | 0.88 | 0.19 | 1.21 | 0.26 |
Small intestine | 0.90 | 0.19 | 1.25 | 0.27 |
Stomach wall | 0.92 | 0.17 | 1.29 | 0.28 |
ULI wall | 0.91 | 0.18 | 1.26 | 0.27 |
Heart wall | 3.82 | 0.55 | 5.60 | 1.20 |
Kidneys | 1.74 | 0.31 | 2.28 | 0.54 |
Liver | 2.43 | 0.38 | 3.19 | 0.64 |
Lungs | 1.87 | 0.34 | 2.44 | 0.48 |
Muscle | 0.75 | 0.15 | 1.05 | 0.22 |
Ovaries | 0.91 | 0.19 | 1.25 | 0.27 |
Pancreas | 1.13 | 0.18 | 1.56 | 0.33 |
Red marrow | 1.25 | 0.17 | 1.84 | 0.43 |
Osteogenic cells | 1.32 | 0.25 | 1.94 | 0.49 |
Skin | 0.55 | 0.12 | 0.77 | 0.17 |
Spleen | 2.14 | 0.42 | 2.76 | 0.63 |
Testes | 0.69 | 0.17 | 0.91 | 0.21 |
Thymus | 1.06 | 0.16 | 1.52 | 0.32 |
Thyroid | 4.16 | 2.19 | 3.66 | 1.88 |
Urinary bladder wall | 2.80 | 0.41 | 2.61 | 0.33 |
Uterus | 0.97 | 0.20 | 1.28 | 0.26 |
Total body | 0.85 | 0.15 | 1.19 | 0.25 |
Effective dose equivalent (cGY/37 MBq) | 1.65 | 0.21 | 2.13 | 0.36 |
Effective dose (cGy/37 MBq) | 1.36 | 0.21 | 1.69 | 0.26 |